This meeting will focus on the oncologic indications of 2-[F-18] Fluoro-D-Glucose (FDG) positron emission tomography (PET) for nine cancers (brain, cervical, small cell lung, ovarian, pancreatic, testicular, prostate, bladder and kidney). The panel will review the scientific evidence of the impact of PET as part of a management strategy to improve patient-centered outcomes. The panel will also consider data generated in accordance with a prior national coverage determination to cover PET for specified cancers when additional data are prospectively collected.
Saty Satya-Murti, MD, FAAN, Acting Chair Steve E. Phurrough, MD, MPA, Coverage and Analysis Group Maria Ellis, Executive Secretary
Download Minutes [PDF, 20KB].
Use the following scale response for each of the questions below.
1
2
3
4
5
No confidence
Equivocal
High confidence
1. How confident are you that the evidence is adequate to conclude that FDG-PET imaging improves physician decision making when used for the following indications for each in these nine cancers?
Bladder
Brain
Cervix
Kidney
Ovary
Pancreas
Prostate
Small Cell Lung
Testis
2. How confident are you that the evidence is adequate to conclude that FDG-PET imaging improves patient oriented clinical outcomes when used for the following indications in each of these nine cancers?
3. How confident are you that these conclusions are generalizable to other cancers?
4. How confident are you that these conclusions are generalizable to non-research PET facilities in the general community?
5. How confident that these conclusions are generalizable to the Medicare beneficiary population?
Saty Satya-Murti, MD, FAAN, Acting Chair Health Policy Consultant
I Craig Henderson, MD Adjunct Professor of Medicine University of California, San Francisco
Nora A. Janjan, MD Professor, Dept of Radiation Oncology University of Texas M.D. Anderson Cancer Center
J. Leonard Lichtenfeld, MD American Cancer Society
Andrew Sloan, MD Staff Neurosurgeon Department of Neurosurgery University Hospitals of Cleveland
Michael Steinberg, MD Professor and Chair Department of Radiation Oncology David Geffen School of Medicine at UCLA
Sean D. Sullivan, PhD Professor of Pharmacy Public Health and Medicine Director Pharmaceutical Outcomes and Research and Policy Program University of Washington
Consumer Representative Linda A. Bergthold, PhD Independent Consultant & Researcher
Industry Representative Peter Juhn, MD, MPH President Therapeutic Resource Centers Medco Health Solutions, Inc.
Guest Panel Member Richard L. Wahl, MD Professor of Radiology and Oncology Henry N. Wagner, Jr. Professor of Nuclear Medicine Director Nuclear Medicine/PET Facility Vice Chair Radiology for Technology and Business Development Johns Hopkins University School of Medicine
Guest Speakers Bruce Hillner, MD Professor Department of Internal Medicine MVC Campus Virginia Commonwealth University
David Mankoff, MD, PhD Seattle, Washington
CMS Liasion Steve E. Phurrough, MD, MPH Director Coverage and Analysis Group
Executive Secretary Maria A. Ellis
